Core Viewpoint - Endeavour Silver Corp. announces significant changes in its Board of Directors and senior management team, marking a new phase of growth and execution as it aims to become a senior silver producer [1][12]. Management Changes - George Paspalas has been appointed to the Board of Directors, effective March 1, 2026, bringing over 40 years of international leadership experience in the mining sector, including his role as President and CEO of MAG Silver Corp. [2][4] - Don Gray, the current Chief Operating Officer, will retire on April 30, 2026, after playing a crucial role in transforming the Terronera project and shaping the company's operational success [5][8]. - Luis Castro has been appointed as the new Chief Operating Officer, effective March 1, 2026, having over 22 years of experience with Endeavour and a strong background in exploration and geology [7][9]. - Gord Bussieres has been appointed as Vice President, Projects, bringing more than 40 years of experience in project development and technical oversight [10][12]. Company Operations and Strategy - Endeavour Silver operates three underground mines in Mexico and Peru, supported by a robust development pipeline aimed at advancing its long-term strategy [1][12]. - The company is focused on building momentum and driving strategic priorities forward under the new leadership, particularly with the development of the Pitarrilla project [9][12].

Core Insights - BD has received FDA 510(k) clearance for the Surgiphor™ 1000mL, the first and only 1000 mL antimicrobial irrigation system designed for powered lavage, enhancing surgical safety and efficiency [1][1][1] Company Overview - BD is a leading global medical technology company focused on advancing healthcare through innovation in medical essentials, connected care, biopharma systems, and interventional solutions [1][1] - The company operates globally with over 60,000 employees and delivers billions of products annually, positively impacting global healthcare [1][1] Product Features - The Surgiphor™ 1000mL provides a standardized, ready-to-use, and sterile solution that simplifies complex surgical procedures, saving time in the operating room [1][1] - Key features include terminally sterile PVPI solution, optimized flow and ergonomics, versatile interchangeability with powered devices, and compatibility with existing powered irrigation setups [1][1][1] Market Position - The FDA clearance reinforces BD's leadership in surgical irrigation innovation, allowing surgical teams to focus on patient care [1][1] - The expanded Surgiphor™ portfolio now includes both manual and powered irrigation configurations, offering flexibility to clinicians [1][1]

Core Viewpoint - Endeavour Silver Corp. is entering a new phase of growth with key appointments to its Board of Directors and senior management team, aiming to advance its long-term strategy and move closer to becoming a senior silver producer [1]. Management Changes - George Paspalas has been appointed to the Board of Directors effective March 1, 2026, bringing over 40 years of international leadership experience in precious and base metals, including his role in developing the Juanicipio silver mine [2][4]. - Don Gray, the current Chief Operating Officer, will retire on April 30, 2026, after significantly contributing to the Terronera project and shaping the Pitarrilla mine's development [5][8]. - Luis Castro has been appointed as the new Chief Operating Officer effective March 1, 2026, having over 22 years of experience with Endeavour and a strong background in exploration and geology [7][9]. - Gord Bussieres has been appointed as Vice President, Projects, bringing over 40 years of experience in project development and technical oversight, which will be crucial for advancing Endeavour's development portfolio [9][10]. Company Overview - Endeavour Silver operates three underground mines in Mexico and Peru and has a robust pipeline of exploration projects across Mexico, Chile, and the United States, positioning itself for organic growth and value creation [11].

Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][12] Clinical Data and Efficacy - The Phase 3 RAPIDe-3 study demonstrated that deucrictibant achieved rapid and sustained symptom relief for HAE attacks, with a median time to onset of symptom relief of 1.28 hours compared to over 12 hours for placebo [3][6] - Deucrictibant met all primary and secondary efficacy endpoints, with 90.4% of treated attacks achieving symptom relief within 12 hours, and a median time to complete resolution of 11.95 hours versus over 48 hours for placebo [3][6] - The long-term safety and efficacy of deucrictibant were supported by the Phase 2 CHAPTER-1 study, showing a reduction in attack rate from 2.18 attacks per month to 0.12 attacks per month over approximately three years [5][7] Quality of Life Improvements - Treatment with deucrictibant resulted in clinically meaningful improvements in health-related quality of life (HRQoL) and higher treatment satisfaction for participants over the long term [8] Novel Biomarker Development - Pharvaris has developed a kinin biomarker assay to measure bradykinin levels in plasma, which may aid in the characterization and management of bradykinin-mediated angioedema [10] Product Development and Regulatory Status - Deucrictibant is being developed in two formulations: an immediate-release capsule for on-demand treatment and an extended-release tablet for prophylactic use [11] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a global pivotal Phase 3 study for the extended-release tablet, with topline data expected in Q3 2026 [12]

Core Viewpoint - The company is facing significant leadership challenges, with calls for immediate reforms in the boardroom and the establishment of a Brand Product Committee to enhance brand strength and shareholder value [1][2]. Group 1: Leadership and Governance - Wilson has urged for a refresh of the boardroom and the formation of a Brand Product Committee, citing a lack of effective engagement from the Board on critical issues [1][4]. - There is a disconnect between the company's creative capabilities and the Board's strategic oversight, which has contributed to a decline in stock price and shareholder value [2]. - Several directors have lost support from over 20% of shareholders, indicating widespread dissatisfaction with the current leadership [3]. Group 2: Financial Performance - Lululemon's stock price has decreased by nearly 50% over the past five years, resulting in an estimated loss of $20 billion in shareholder value [2]. - The company is currently experiencing a crisis in hiring a new permanent CEO, attributed to a failed succession planning process [3]. Group 3: Engagement and Proposals - Wilson's proposal for a Brand Product Committee was rejected by the Board, despite its success in other companies [6]. - The Board's engagement with Wilson's proposed changes has been criticized as slow and insufficient, with significant delays in response times [5].

Core Viewpoint - Theon International Plc is hosting a webcast on March 6, 2026, to discuss its investment case, business model, operations, recent news, financial results, and outlook [2][3]. Group 1: Webcast Details - The webcast will be led by Philippe Mennicken, Deputy CEO and Business Development Director [3]. - It is open to all existing and potential investors, with a live Q&A session available [3]. - Investors can register for free on the Investor Meet Company platform [3]. Group 2: Company Overview - Theon Group develops and manufactures advanced night vision and thermal imaging systems for defense and security applications [5]. - Established in 1997 in Greece, Theon Group has a significant international presence with subsidiaries and production facilities in multiple countries, including the US, Germany, and South Korea [5]. - The company has over 250,000 systems in service across 72 countries, including 26 NATO member countries [5]. - Theon International Plc has been listed on Euronext Amsterdam since February 2024 [5].

Core Viewpoint - Lloyds Bank is transitioning to a fully online account opening process, discontinuing in-person account openings at branches, which reflects a broader trend towards digital banking services [1][2][5] Group 1: Changes in Account Opening Process - Customers are now required to open joint, premium, and student accounts online rather than in person at branches [1] - Internal documents indicate that staff will guide customers to use digital platforms for account openings and switching banks [1][3] - The transition to digital account openings will commence next month and is expected to be completed by May [5] Group 2: Impact on Branch Network - Lloyds Bank has announced over 100 additional branch closures, adding to the 1,470 branches closed in the past decade, leaving 610 branches remaining after the current closure program [2][3] - Certain services, such as opening executor accounts or making bankruptcy and overdraft appeals, will no longer be available in branches [3] Group 3: Customer Demographics and Digital Adoption - Lloyds Banking Group serves 28 million customers, with nearly five million not utilizing digital services [4] - The new approach is anticipated to impact basic accounts aimed at customers facing financial hardship [4] - Chief executive Charlie Nunn noted that 97% of customer interactions are now digital, emphasizing recent hiring in technology and data roles [4]

Airlines and cruise operators were among the worst hit stocks ahead of the open Monday as the travel sector faced up to escalating conflict in the Middle East. ...

Core Viewpoint - Venture Global forecasts lower adjusted core profit for 2026 due to the impact of Winter Storm Fern and margin compression in the first quarter [1] Company Performance - Venture Global's revenue nearly tripled to $4.4 billion in Q4, with net income rising 23% to $1.07 billion, driven by higher LNG sales volumes from the Plaquemines Project [1] - The company expects 2026 adjusted core earnings to be between $5.20 billion and $5.80 billion, below analysts' average estimate of $6.03 billion [1] Industry Context - U.S. LNG exports fell to 11.3 million metric tonnes in January from 11.5 million metric tonnes in December due to winter weather affecting production [1] - The U.S. became the first country to export over 100 million metric tonnes of LNG in a single year in 2025, aided by new plant startups [1] - The trend of selling LNG under long-term contracts is squeezing margins, limiting companies' ability to benefit from short-term price increases [1] Future Contracts and Expectations - Venture Global signed a five-year agreement with Trafigura to supply approximately 0.5 million metric tonnes per annum of LNG starting in 2026, increasing total contracted quantities to nearly 9.75 million metric tonnes per annum [1] - The company anticipates exporting 145 to 156 cargoes from the Calcasieu Project and 341 to 371 cargoes from the Plaquemines Project in 2026 [1]

Core Viewpoint - Everest Group (EG) shares have underperformed over the past year, with a loss of approximately 3% in value [1] Group 1: Company Performance - The company benefited from a quiet hurricane season, which was a significant positive factor [1] - However, challenges with legacy policies necessitated Everest to increase reserves and reinsure some of its risks [1]